KPRX
NASDAQKiora Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks29+60%
2025-12-282026-06-21
Mix2390d
- SEC Filings13(57%)
- Insider9(39%)
- Other1(4%)
Latest news
25 items- SECKiora Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- PRKiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy ModelData Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase 2 clinical program in vision restoration in patients with gene mutation-agnostic Retinitis PigmentosaEncinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ:KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundatio
- INSIDERSEC Form 4 filed by Director Stengone Carmine N.4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Director Shapiro Aron4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Director Parsons Erin4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Director Hollander David4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Director Walters-Hoffert Lisa4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Director Tyle Praveen4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- SECSEC Form 424B3 filed by Kiora Pharmaceuticals Inc.424B3 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form EFFECT filed by Kiora Pharmaceuticals Inc.EFFECT - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form S-3 filed by Kiora Pharmaceuticals Inc.S-3 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECKiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form 10-Q filed by Kiora Pharmaceuticals Inc.10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form DEF 14A filed by Kiora Pharmaceuticals Inc.DEF 14A - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form D filed by Kiora Pharmaceuticals Inc.D - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECKiora Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- INSIDERSEC Form 4 filed by Tosca Melissa4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Daniels Eric Joseph4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Strem Brian M.4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- SECKiora Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form S-8 filed by Kiora Pharmaceuticals Inc.S-8 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECKiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form 10-K filed by Kiora Pharmaceuticals Inc.10-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- INSIDERSEC Form 4 filed by Kiora Pharmaceuticals Inc.4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Kiora Pharmaceuticals Inc.4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
KPRX FAQ
6 questionsWhat does Kiora Pharmaceuticals Inc. do?
Kiora Pharmaceuticals, Inc., an ophthalmic specialty pharmaceutical company, develops therapies for the treatment of eye diseases in the United States. Its pipeline includes KIO-101, a small molecule DHODH inhibitor that treats immunologic eye diseases; KIO-201, an eye drop that enhances ocular wound healing and protects the ocular surface; and KIO-301, a small molecule that has the potential to restore vision in patients with inherited or age related retinal degeneration. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in...Where does KPRX stock trade?
Kiora Pharmaceuticals Inc. (KPRX) is listed on NASDAQ.What sector and industry is KPRX in?
Kiora Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about KPRX?
Kiora Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $250.00 price target on 2022-01-19. Recent price targets cluster around $250.00.What companies are similar to KPRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KPRX side-by-side with any of them on Quantisnow.How can I track KPRX on Quantisnow?
Quantisnow aggregates Kiora Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KPRX to receive live email and push alerts on every new disclosure.